Novartis AG (NVS)
| Previous Close | 97.09 |
| Open | 97.08 |
| Bid | 97.07 x 800 |
| Ask | 97.08 x 800 |
| Day's Range | 96.93 - 97.82 |
| 52 Week Range | 92.19 - 108.78 |
| Volume | |
| Avg. Volume | 1,648,904 |
| Market Cap | 198.491B |
| Beta (5Y Monthly) | 0.47 |
| PE Ratio (TTM) | 22.08 |
| EPS (TTM) | 4.40 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 3.78 (3.89%) |
| Ex-Dividend Date | Mar 07, 2024 |
| 1y Target Est | 114.51 |
ZacksAre You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
ZacksWhy This 1 Value Stock Could Be a Great Addition to Your Portfolio
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
ReutersMorphosys says takeover by Novartis on course after report of drug safety concern
BERLIN (Reuters) -Morphosys said its takeover by Novartis is still expected to close in the first half of this year, after a news report on a possible drug safety risk knocked the German biotechnology company's stock price on Monday. Morphosys' statement came after a report by specialist website STAT News, citing two people familiar with the matter, of a safety issue with its experimental drug pelabresib, which is being developed to treat myelofibrosis, a rare type of blood cancer affecting the bone marrow.
